Cargando…

ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer

Head and neck cancer is a highly genetic and metabolic heterogeneous collection of malignancies of the lip, oral cavity, salivary glands, pharynx, esophagus, paranasal sinuses, and larynx with five-year survival rates ranging from 12% to 93%. Patients with head and neck cancer typically present with...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Gan, Pan, Shu-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396055/
https://www.ncbi.nlm.nih.gov/pubmed/32774675
http://dx.doi.org/10.1155/2020/5047987
_version_ 1783565511028637696
author Huang, Gan
Pan, Shu-Ting
author_facet Huang, Gan
Pan, Shu-Ting
author_sort Huang, Gan
collection PubMed
description Head and neck cancer is a highly genetic and metabolic heterogeneous collection of malignancies of the lip, oral cavity, salivary glands, pharynx, esophagus, paranasal sinuses, and larynx with five-year survival rates ranging from 12% to 93%. Patients with head and neck cancer typically present with advanced stage III, IVa, or IVb disease and are treated with comprehensive modality including chemotherapy, radiotherapy, and surgery. Despite advancements in treatment modality and technique, noisome recurrence, invasiveness, and resistance as well as posttreatment complications severely influence survival rate and quality of life. Thus, new therapeutic strategies are urgently needed that offer enhanced efficacy with less toxicity. ROS in cancer cells plays a vital role in regulating cell death, DNA repair, stemness maintenance, metabolic reprogramming, and tumor microenvironment, all of which have been implicated in resistance to chemo-/radiotherapy of head and neck cancer. Adjusting ROS generation and elimination to reverse the resistance of cancer cells without impairing normal cells show great hope in improving the therapeutic efficacy of chemo-/radiotherapy of head and neck cancer. In the current review, we discuss the pivotal and targetable redox-regulating system including superoxide dismutases (SODs), tripeptide glutathione (GSH), thioredoxin (Trxs), peroxiredoxins (PRXs), nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/keap1), and mitochondria electron transporter chain (ETC) complexes and their roles in regulating ROS levels and their clinical significance implicated in chemo-/radiotherapy of head and neck cancer. We also summarize several old drugs (referred to as the non-anti-cancer drugs used in other diseases for a long time) and small molecular compounds as well as natural herbs which effectively modulate cellular ROS of head and neck cancer to synergize the efficacy of conventional chemo-/radiotherapy. Emerging interdisciplinary techniques including photodynamic, nanoparticle system, and Bio-Electro-Magnetic-Energy-Regulation (BEMER) therapy are promising measures to broaden the potency of ROS modulation for the benefit of chemo-/radiotherapy in head and neck cancer.
format Online
Article
Text
id pubmed-7396055
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73960552020-08-07 ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer Huang, Gan Pan, Shu-Ting Oxid Med Cell Longev Review Article Head and neck cancer is a highly genetic and metabolic heterogeneous collection of malignancies of the lip, oral cavity, salivary glands, pharynx, esophagus, paranasal sinuses, and larynx with five-year survival rates ranging from 12% to 93%. Patients with head and neck cancer typically present with advanced stage III, IVa, or IVb disease and are treated with comprehensive modality including chemotherapy, radiotherapy, and surgery. Despite advancements in treatment modality and technique, noisome recurrence, invasiveness, and resistance as well as posttreatment complications severely influence survival rate and quality of life. Thus, new therapeutic strategies are urgently needed that offer enhanced efficacy with less toxicity. ROS in cancer cells plays a vital role in regulating cell death, DNA repair, stemness maintenance, metabolic reprogramming, and tumor microenvironment, all of which have been implicated in resistance to chemo-/radiotherapy of head and neck cancer. Adjusting ROS generation and elimination to reverse the resistance of cancer cells without impairing normal cells show great hope in improving the therapeutic efficacy of chemo-/radiotherapy of head and neck cancer. In the current review, we discuss the pivotal and targetable redox-regulating system including superoxide dismutases (SODs), tripeptide glutathione (GSH), thioredoxin (Trxs), peroxiredoxins (PRXs), nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/keap1), and mitochondria electron transporter chain (ETC) complexes and their roles in regulating ROS levels and their clinical significance implicated in chemo-/radiotherapy of head and neck cancer. We also summarize several old drugs (referred to as the non-anti-cancer drugs used in other diseases for a long time) and small molecular compounds as well as natural herbs which effectively modulate cellular ROS of head and neck cancer to synergize the efficacy of conventional chemo-/radiotherapy. Emerging interdisciplinary techniques including photodynamic, nanoparticle system, and Bio-Electro-Magnetic-Energy-Regulation (BEMER) therapy are promising measures to broaden the potency of ROS modulation for the benefit of chemo-/radiotherapy in head and neck cancer. Hindawi 2020-07-22 /pmc/articles/PMC7396055/ /pubmed/32774675 http://dx.doi.org/10.1155/2020/5047987 Text en Copyright © 2020 Gan Huang and Shu-Ting Pan. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Huang, Gan
Pan, Shu-Ting
ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title_full ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title_fullStr ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title_full_unstemmed ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title_short ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
title_sort ros-mediated therapeutic strategy in chemo-/radiotherapy of head and neck cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396055/
https://www.ncbi.nlm.nih.gov/pubmed/32774675
http://dx.doi.org/10.1155/2020/5047987
work_keys_str_mv AT huanggan rosmediatedtherapeuticstrategyinchemoradiotherapyofheadandneckcancer
AT panshuting rosmediatedtherapeuticstrategyinchemoradiotherapyofheadandneckcancer